Gracell to Start China Trial of CAR-T in Leukemia Patients

Suzhou 's Gracell Biotech will start a China trial of its FasTCAR cell therapy in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). GC019F modifies a patient's own T-Cells to express CD19 via a Gracell process that reduces manufacturing time from an average of four weeks to 22 to 36 hours. Gracell believes its platform produces less exhausted, more potent CAR-T cells than the competition. Last week, Gracell said it will start a US trial of a donor-derived CAR-T candidate, also in B-ALL patients. More details.... Stock Symbol: (NSDQ: GRCL) Share this with colleagues: // //